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Abstract
Background: Acute otitis media (AOM) is one of the most frequently encountered bacterial infections in children
aged < 5 years; Streptococcus pneumoniae (S. pneumoniae) and non-typeable Haemophilus influenzae (NTHi) are
historically identified as primary AOM causes. Nevertheless, recent data on bacterial pathogens causing AOM in
Latin America are limited. This prospective study aimed to identify and characterize bacterial etiology and
serotypes of AOM cases including antimicrobial susceptibility in < 5 year old Colombian children.
Methods: From February 2008 to January 2009, children ≥3 months and < 5 years of age presenting with AOM
and for whom a middle ear fluid (MEF) sample was available were enrolled in two medical centers in Cali,
Colombia. MEF samples were collected either by tympanocentesis procedure or spontaneous otorrhea swab
sampling. Bacteria were identified using standard laboratory methods, and antimicrobial resistance testing was
performed based on the 2009 Clinical and Laboratory Standards Institute (CLSI) criteria. Most of the cases included
in the study were sporadic in nature.
Results: Of the 106 enrolled children, 99 were included in the analysis. Bacteria were cultured from 62/99 (63%) of
samples with S. pneumoniae, H. influenzae, or S. pyogenes. The most commonly isolated bacteria were H. influenzae
in 31/99 (31%) and S. pneumoniae in 30/99 (30%) of samples. The majority of H. influenzae episodes were NTHi (27/
31; 87%). 19F was the most frequently isolated pneumococcal serotype (10/30; 33%). Of the 30 S. pneumoniae
positive samples, 8/30 (27%) were resistant to tetracycline, 5/30 (17%) to erythromycin and 8/30 (27%) had
intermediate resistance to penicillin. All H. influenzae isolates tested were negative to beta-lactamase.
Conclusions: NTHi and S. pneumoniae are the leading causes of AOM in Colombian children. A pneumococcal
conjugate vaccine that prevents both pathogens could be useful in maximizing protection against AOM.
Background
Acute otitis media (AOM) is one of the most frequent
bacterial infections in infancy and early childhood
worldwide. Though diagnosed in all ages, AOM is rela-
tively common among children between six months to
three years of age with approximately 80% of children
having had at least one episode of AOM by the time
they are three years old [1]. AOM is one of the main
causes of childhood morbidity in both developed and
developing countries [2]. The estimated annual disease
burden of AOM ranges between 8,200,000 and
12,900,000 cases among children less than five years of
age in Latin America and the Caribbean [3], compared
to that in US children [4] where the estimated number
of AOM per year are 10,200,000. In Europe, the high
incidence of AOM during childhood has been con-
firmed, estimated to range from 17,600 to 38,700 epi-
sodes per 100,000 person-years in children under five
years of age [5].
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the most serious infections are believed to involve bac-
terial pathogens [6], particularly Streptococcus pneumo-
niae (S. pneumoniae) or non-typeable Haemophilus
influenzae (NTHi), which together account for at least
60-70% of clinical AOM episodes [7]. Other less fre-
quently reported bacterial agents of AOM are Moraxella
catarrhalis (M. catarrhalis), Streptococcus pyogenes (S.
pyogenes)a n dStaphylococcus aureus (S. aureus) [8,9].
Limited studies from Latin America have suggested that
S. pneumoniae is the most common bacterial pathogen
found in middle ear fluid samples from AOM cases
[10,11]. However, in recent years, Haemophilus influen-
zae( H. influenzae) is increasingly being recognized as a
prominent bacterial pathogen in AOM [11,12]. In addi-
tion, many of the AOM etiology studies referred to
above are centered on treatment failure or persistent
AOM patients and not sporadic cases even though the
latter represent the vast majority of AOM, and thus,
even the global data may not reflect the true etiology of
the most common form of AOM [13].
Although some AOM cases resolve spontaneously, the
majority receives antibiotic treatment in order to diminish
the duration of symptoms and increase the likelihood of
resolution [14]; AOM is one of the primary reasons for
pediatricians to prescribe antibiotics [15-17]. Constant use
of antibiotics over the years has led to an increase in resis-
tance/non-susceptibility to antibiotics of the bacterial
pathogens. Some of the antibiotic-resistant serotypes of S.
pneumoniae are the ones that are most often involved in
serious pneumococcal infections [18]. In Latin America,
the serotypes 6A, 6B, 9V, 14, 19A, 19F, and 23F are
responsible for most of the antibiotic-resistant
S. pneumoniae infections that cause invasive disease in
children [19]. According to the Surveillance reports of
the Regional System for Vaccines (SIREVA), coordinated
by the Microbiology Group of the National Institute of
Health of Colombia, of the 90 different serotypes of
S. pneumoniae identified so far, serotype 14 is the most
frequently isolated serotype in Colombia for invasive
pneumococcal disease [20].
Widespread immunization of children with pneumo-
coccal conjugate vaccines might play a role in reducing
AOM episodes. The heptavalent pneumococcal conju-
gate vaccine (Prevnar™/Prevenar™, Pfizer/Wyeth, USA;
PCV-7) was introduced as public immunization for US
children in 2000. In clinical efficacy trials, this vaccine
had previously been shown to have 57% efficacy against
vaccine-type pneumococcal AOM [21], and overall 7%
efficacy against clinical AOM episodes [22]. With the
use of antibiotics at high doses and PCV-7, there has
been a change in the pneumococcal serotypes responsi-
ble for persistent AOM and an increasing predominance
of H. influenzae [23,24].
In the recently licensed 10-valent pneumococcal/H.
influenzae protein D conjugate vaccine (Synflorix™, Glax-
oSmithKline [GSK] Biologicals, Rixensart, Belgium;
PHiD-CV) that contains the same serotypes as found in
PCV-7 plus the invasive serotypes 1, 5, and 7F, 8 of the
10 serotypes are conjugated to a recombinant form of
protein D of non-typeable H. influenzae. A randomized,
double-blind, controlled study with a prototype
11-valent protein D formulation suggests that PHiD-CV
may provide similar protection against pneumococcal
AOM as that seen with PCV7 and additional protection
(35%) against episodes of AOM caused by NTHi [25]. A
13-valent pneumococcal vaccine formulation (PCV-13)
is yet to be licensed in Colombia.
Current data on etiology of AOM in Colombian chil-
dren are limited and scarce, with one study on Colom-
bian children with AOM conducted over 20 years ago
[6]. After the 7-valent pneumococcal conjugate vaccine
was introduced in the Colombian private markets in
early 2002, it remains important to characterize the bac-
teria responsible for AOM and to evaluate the potential
impact and effectiveness of vaccination with conjugate
vaccines against H. influenzae and/or pneumococcal
AOM. This prospective study aims to identify and char-
acterize bacterial etiology and serotypes including anti-
microbial susceptibility of AOM in Colombian children
less than five years of age.
Methods
Study design and subjects
This is a prospective epidemiological study conducted in
routine clinical setting at two medical centers in Cali,
Colombia. Children between three months and five
years of age, visiting two pediatric clinics for AOM from
February 2008 to January 2009, and for whom a middle
ear fluid (MEF) sample was available were enrolled in
the study.
The study included children visiting the pediatrician
with one of the general signs for AOM (otalgia/irritabil-
ity, conjunctivitis, fever and either Paradise’s criteria
(bulging, diffused, or localized inflamed tympanic mem-
branes) or spontaneous otorrhea (less than 24 hours).
Patients identified for recruitment were either children
w i t han e we p i s o d eo fA O M( l e s st h a n7 2h o u r so f
onset) who had not yet received antibiotics for the epi-
sode (untreated group), or children who had a diagnosis
of AOM within 48-72 hours prior to study enrolment,
and who received antibiotic therapy from a physician
but remained symptomatic at the time of study entry
(treatment failures). Children who received systemic
antibiotic treatment for a disease other than AOM in
the 72 hours prior to enrolment and ones receiving anti-
microbial prophylaxis for recurrent AOM were
excluded. Recurrent AOM was defined as ≥ 3e p i s o d e s
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months. There were no restrictions on antibiotic use fol-
lowing tympanocentesis. All children were treated
according to local practices.
The primary endpoints were occurrence of H. influenzae,
S. pneumoniae and other bacterial pathogens isolated
from MEF samples. Secondary endpoints were occur-
rence of H. influenzae and S. pneumoniae specific
serotypes.
Written informed consent was obtained from the par-
ent/guardian of the child before conducting any study-
related procedures. Demographic information and
child’s medical history, case history and general symp-
toms were collected and a clinical examination was
performed.
The study included only sporadic cases once they
received attention at the study sites using standard cri-
teria accepted internationally for AOM and using stan-
dard methods to detect bacterial agents avoiding
selection bias.
Bacterial identification and characterization
Samples of MEF for all children were collected by an
ENT specialist by tympanocentesis or by careful sam-
pling of spontaneous otorrhea for children who had
spontaneous/accidental rupture of the tympanic mem-
brane. The latter entailed removing and cleaning the ear
canal by deep aspiration of the MEF material through
the perforation to minimize contamination and spurious
results. For the purposes of this study, only S. pneumo-
niae, NTHi, S. pyogenes and M. catarrhalis were consid-
ered true pathogens [26].
Inoculation of samples was done into Amies transport
medium and the sample was plated at the GSK designed
laboratory within the first 48 hours at room temperature
for further analysis. Standard methodology was
employed in order to determine the antimicrobial sus-
ceptibility. The cut-offs for susceptibility and resistances
are provided in Table 1. The samples were coded with
the identification number for the child.
Statistical analyses
The analysis was performed on the According-To-Pro-
tocol (ATP) cohort (evaluable subjects meeting all
eligibility criteria, complied with the protocol defined
procedures, with no elimination criteria during the
study and for whom laboratory results of the middle ear
fluid sample were available). A recurrent AOM episode
was the third or more episode in the last six months or
the fourth or more episode in the last 12 months.
The proportions of AOM caused by S. pneumoniae, H.
influenzae and other bacterial pathogens were calculated
with their 95% confidence interval (CI). Distribution
analysis of S. pneumoniae and H. influenzae serotypes
by age, by procedure and by pneumococcal vaccination
status for AOM cases was performed. Seasonality of
AOM cases was also determined.
All statistical analyses were performed using statistical
analysis system (SAS) version 9.1 and Microsoft Excel
(for graphical purposes).
Ethics
The study was conducted according to Good Clinical
Practice guidelines, the Declaration of Helsinki and the
local rules and regulations of the country. All the study-
related documents were reviewed and approved by the
local Independent Ethics Committee and the study
adhered to applicable local guidelines.
Results
Demography
During the 12-month period, a total of 106 (103
untreated and 3 treatment failures) children were
enrolled; all reporting one episode each. Of these, seven
Table 1 Ranges for S. pneumoniae and H. influenzae
antimicrobial susceptibility ote: of companies
theentioned in the results now. 36-47 months age group.
ren: Potential implications for pneumococcal con
Antibiotic Susceptible (S) (μg/
mL)
Resistant (R) (μg/
mL)
S. pneumoniae
Penicillin ≤ 0.06 ≥ 2
Cefotaxime ≤ 0.06 ≥ 4
Ceftriaxone ≤ 0.06 ≥ 4
Chloramphenicol ≤ 2 ≥ 32
Erythromycin ≤ 0.06 ≥ 1
Levofloxacin ≤ 0.5 ≥ 8
Linezolid ≤ 2 ≥ 4
Moxifloxacin ≤ 0.25 ≥ 4
Ofloxacin ≤ 1 ≥ 8
Tetracycline ≤ 1 ≥ 16
Trimethoprim/
sulfamethoxazole
≤ 0.5/9.5 ≥ 16/304
Vancomycin ≤ 1 ≥ 2
H. influenzae
Ampicillin ≤ 1> 1
Amoxicillin-clavulanate ≤ 1> 1
Cefotaxime ≤ 0.12 > 0.12
Cefuroxime ≤ 1> 2
Cefuroxime axetil ≤ 0.12 > 1
Levofloxacin ≤ 1> 1
Erythromycin ≤ 0.5 > 16
Tetracycline ≤ 1> 2
Chloramphenicol ≤ 1> 2
Trimethoprim-
sulfamethoxazole
≤ 0.5 > 1
Source: CLSI 2008 - M100-S19- PAGE 65 and 66
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children (treatment failure) received medication (amoxi-
cillin and cefalexin) forbidden in the protocol, one child
(treatment failure) had an onset of signs and symptoms
of AOM beyond 72 hours of diagnosis, MEF samples
could not be collected from three cases, and one child
was enrolled twice for the same episode (elimination at
the second episode). All 99 (93%) children included in
the ATP analyses were untreated with antibiotics; of
these, seven cases were classified as recurrent AOM epi-
sodes. One child had a bilateral episode. No treatment
failures were included in the ATP cohort since none
met the enrolment criteria.
The mean age of children was 28.5 months and 54/99
(55%) were males (Table 2). The highest percentage of
episodes was reported among children 12-23 months and
24-35 months of age 27/99 (27% each). No statistically
significant differences of pathogen distribution by demo-
graphic characteristics were noted. Majority of the epi-
sodes were positive for at least one S. pneumoniae, H.
influenzae or S. pyogenes among children 3-11 months
(9/11, 82%), 12-23 months 17/27 (63%), and 24-35
months (18/27; 67%) of age. H. influenzae was isolated in
all age groups described for this study, 45% (14/31) of
these isolates corresponded to children under 2 years of
age and reporting the same number of cases in children
3-11 and 12-23 months (n = 7). On the other hand, S.
pneumoniae was not isolated in children 48-59 months.
Among these isolates, 40% (12/30) occurred in children
less than 24 months of age, distributed as 3 isolates in
children 3-11 (10%) and 9 in 12-23 months (30%).
More females were positive (31/45, 69%) for at least
one study bacteria than males (30/54, 56%). No statisti-
cally significant differences of pathogen distribution by
gender characteristics were identified. Of the seven
recurrent cases, four (15%) belonged to the 36-47
months age group.
Seasonality
AOM episodes occurred throughout the year; however,
the maximum number of cases was enrolled between
February and April 2008 with a smaller peak occurring
in August 2008 corresponding to the rainy season in
Cali. H. influenzae was isolated during all months, with
higher prevalence in August (n = 7), February (n = 5),
and March (n = 5). S. pneumoniae was predominantly
isolated in February (n = 7) and June (n = 5), but also
found throughout the year (Figure 1).
Sample Collection
Only one MEF sample was collected from 98/99 AOM
untreated episodes (one episode had two samples col-
lected, one from each ear). Of the 99 untreated episodes,
84/99 (85%) of samples were collected by tympanocent-
esis and 16/99 (16%) by spontaneous otorrhea.
Bacterial etiology
Pathogenic bacteria were cultured from 62/99 (63%) of
episodes with the bacterium: S. pneumoniae, H. influen-
zae, or S. pyogenes. Over 13/16 (81%) of episodes col-
lected by otorrhea swab were bacterial positive,
compared to 49/83 (59%) collected by tympanocentesis.
Overall, 68 bacterial agents were isolated, corresponding
to 56 episodes with a single pathogen and 6 episodes
with 2 pathogens. The most commonly isolated bacteria
were H. influenzae in 31/99 (31%) and S. pneumoniae in
30/99 (30%) of episodes, with S. pyogenes representing
only 2/99 (2%) of cases and other bacteria in 5/99 (5%)
cases (Figure 2). Samples collected from two children
were positive for both S. pneumoniae and H. influenzae.
No samples tested positive for M. catarrhalis.M o s to f
H. influenzae and S. pneumoniae isolates were taken by
tympanocentesis (77% and 83%, respectively). From 83
samples collected by tympanocentesis, 30.1% isolated S.
pneumoniae and 28.9% isolated H. influenzae;a n df r o m
16 samples collected by otorrhea, 43.8% corresponded
to H. influenzae and 31.3% to S. pneumoniae. H. influen-
zae was isolated in 6/7 recurrent AOM episodes, mean-
while S. pneumoniae was isolated in only 1/7 recurrent
AOM.
At least one dose of the pneumococcal vaccine was
received by 29/99 (29%) of children. The percentage of
children who received at least one dose of heptavalent
pneumococcal conjugate vaccine (PCV-7) was 30%
(9/30) include numbers as for H influenza bleow) in
children who were culture positive for S. pneumoniae
(seven fully vaccinated and two partially vaccinated) and
35% who were culture positive for H. influenzae (11/31).
Serotype distribution of H. influenzae and S. pneumoniae
The majority of H. influenzae isolated were non-typeable
(27/31; 87%). NTHi was isolated from all H influenzae
episodes in the 3-11 months, 12-23 months and 48-59
months age groups. In children under two years of age,
all isolates corresponded to being non-typeable, mean-
while, 4/17 (24%) encapsulated isolates were identified
in the 24-60 months age groups corresponding to f and
b serotypes; the remaining 2 isolates were unknown.
Serotype 19F was the most frequently isolated pneu-
mococcal serotype followed by 6A and 14. Serotypes 3
and 19A were the fourth most prevalent (Figure 3). The
majority of the serotypes (3, 6A, 14, 16F, 19F, 20, 23F)
were isolated in the 12-23 months age group. In fully
vaccinated children, serotypes 19F (n = 4), 19A (n = 2)
and 6A (n = 1) were isolated. Serotypes 6A and 3 were
isolated in the partially vaccinated children.
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Page 4 of 11Table 2 Demographic characteristics with bacterial etiology of episodes by age and gender (ATP cohort)
AOM Episodes Characteristics Categories Value or n %
Age (months) -
Mean 28.5 -
SD 13.03 -
Median 29 -
Range 5-55 -
Age group (months)
0-11
a 11 11.1%
H. influenzae 7-
S. pneumoniae 3-
S. pyogenes 0-
Others/Negative 5 -
12-23
b 27 27.3%
H. influenzae 7-
S. pneumoniae 9-
S. pyogenes 1-
Others/Negative 11 -
24-35 27 27.3%
H. influenzae 5-
S. pneumoniae 12 -
S. pyogenes 1-
Others/Negative 9 -
36-47
c 26 26.3%
H. influenzae 8-
S. pneumoniae 6-
S. pyogenes 0-
Others/Negative 13 -
48-59 8 8.1%
H. influenzae 4-
S. pneumoniae 0-
S. pyogenes 0-
Others/Negative 4 -
Gender
Female
d 45 45.5%
H. influenzae 17 -
S. pneumoniae 14 -
S. pyogenes 1-
Others/Negative 17 -
Male
e 54 54.5%
H. influenzae 14 -
S. pneumoniae 16 -
S. pyogenes 1-
Others/Negative 25 -
N = 99; number of episodes.
n = number of episodes in a given category.
% = n/Number of samples with results available * 100.
aIt includes 3 episodes with more than 1 bacterial isolate (S. pneumoniae + H. influenzae+others; S. pneumoniae + others; H. influenzae + others).
bIt includes 1 episode with more than 1 bacterial isolate (S. pneumoniae + others).
cIt includes 1 episode with more than 1 bacterial isolate (S. pneumoniae + H. influenzae).
dIt includes 3 episodes with more than 1 bacterial isolate (S. pneumoniae + H. influenzae+others; S. pneumoniae + others; H. influenzae + others).
eIt includes 2 episodes with more than 1 bacterial isolate (S. pneumoniae + H. influenzae; S. pneumoniae + others).
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The prevalence of sensitive, intermediate and resistant
strains for penicillin, among the 30 S. pneumoniae positive
samples from episodes, were 21/30 (70%), 8/30 (27%) and
1/30 (3%), respectively (Figure 4). The strains resistant to
other antibiotics were: 1/30 (3%) to cefotaxime, 5/30 (17%)
to erythromycin and 8/30 (27%) to tetracycline and sulfa-
methoxazole/trimethoprim (Table 3). From S. pneumoniae
isolates, serotype 19F evidenced antibiotic resistance to
tetracycline (50%; 5/10), trimethoprim/sulfamethoxazole
(30%; 3/10) and erythromycin (20%; 2/20); serotype 19A
was resistant to penicillin, cefotaxime, tetracycline and
erythromycin (50%; n = 1/2), respectively.
All H. influenzae (n = 31) tested with ampicillin were
sensitive. From these isolates, 30 were tested for nitroce-
fin (beta-lactamase test) and reported as negative. All
H. influenzae samples tested for penicillin (11/11) and
for amoxicillin/clavulanate (26/26) were sensitive.
Discussion
Historically, the major bacteria responsible for most
cases of AOM microbiology worldwide does not appear
to have changed significantly over time, but the relative
prevalence of main causal agents have changed in recent
years [9]. In this study, approximately 63% of the sam-
ples cultured pathogenic bacteria. This proportion is in
line with that seen in another study [27].
H. influenzae and S. pneumoniae are identified as the
main causative agents of AOM in the current study,
accounting for 31% and 30% of episodes, respectively.
These results are similar to findings from other studies
conducted in Latin American countries including Argen-
tina [28], Chile [11], Costa Rica [10,29] and Mexico [30]
where the leading causes of bacterial AOM were S. pneu-
moniae and H. influenzae. The studies in Argentina, Chile
and Mexico looked at sporadic cases; this study shows
that major pathogens in sporadic cases are similar to the
mentioned studies. Increasing recognition of H. influenzae
overtaking S. pneumoniae as the most frequent cause of
AOM has recently been observed [9]. A previous study in
the United States (1995-2003) assessed the changes in fre-
quency and pathogens causing AOM since introduction of
PCV-7 and reported a significant decrease in S. pneumo-
niae and an increase in H. influenzae among MEF isolates
suggesting that H. influenzae has become the predominant
pathogen of AOM since the inclusion of pneumococcal
conjugate vaccine in the universal immunization program
[13,23]. No significant differences in culture positivity by
demographic characteristics and pneumococcal vaccina-
tion status were noted in this study with 66% of vaccinated
and 61% of unvaccinated children being culture positive
for at least one bacteria. However, vaccinated children
showed a trend towards non-typeable H. influenzae (35%)
compared to S. pneumoniae (30%).
Figure 1 Seasonal distribution of AOM episodes (ATP cohort). The stacked line graph shows the number of episodes enrolled in each
month and the simple bar graph shows the number of S. pneumoniae and H. influenzae isolated each month.
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groups, including during the first two years of life. This
finding evidences the major role of this pathogen not
only in older subjects as have been previously reported,
but also in the younger children where the prominence
of H. influenzae was not expected. Also, H. influenzae
was present in most of the samples collected by otor-
rhea which is opposite from the findings in previous
reports where most of otorrhea samples corresponded
to S. pneumoniae. NTHi was responsible for 27/31
(87%) H. influenzae AOM episodes in this study. NTHi
has shown to account for more recurrent AOM com-
pared to S. pneumoniae and S. pyogenes and is asso-
ciated with a history of recurrent AOM episodes,
treatment failure and AOM within two weeks of com-
pleting a course of any antibiotic [31], making it a diffi-
cult-to-treat pathogen. This was confirmed in this study
also where 6/7 recurrent AOM cases were due to NTHi.
Similar to previous reports, M. catarrhalis and S. pyo-
genes were not major pathogens in this study [28,32,33].
Increase of resistance of S. pneumoniae to penicillin
and other antibiotics is a concern in Latin America [34].
However, the current study shows limited prevalence of
penicillin resistant S. pneumoniae but 8/30 (27%) had
intermediate resistance to penicillin. Consistent with the
findings in Colombia [6], Costa Rica [10] and USA [35],
all H. influenzae strains tested were beta-lactamase-
negative in this study suggesting that both amoxicillin as
well as amoxicillin/clavulanate could be considered as
an AOM treatment option [36].
From the reported pneumococcal serotypes in this
study, 19F was the most frequently isolated pneumococ-
cal serotype in this study, followed by 6A and 14. That
four 19F cases were detected in fully vaccinated children
appears consistent with the results of the PCV7 AOM
efficacy trial conducted in Finland, where the lowest
Figure 2 Etiology of bacteria identified from samples cultured from middle ear fluid. Number of positive bacterial episodes is represented
in the stacked column bar. The bar for H. influenzae also includes serotypes of H. influenzae positive episodes. * H. influenzae type b ** H.
influenzae type f
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19F, at 25% (95% CI -14 to 51) [21]. In this study, 3 and
19A together represented 13% of the pneumococcal
AOM. Serotype 14 has previously been documented to
be the most frequent in Colombia [20]. Similar to stu-
dies in Costa Rica [10,37] and Chile [11], 19F was the
most frequently isolated pneumococcal serotype in this
study, followed by 6A and 14. Global data shows the
most common pneumococcal serotypes causing AOM
are 3, 6A, 6B, 9V, 14, 19A, 19F and 23F [38] indicating
that potential coverage for pneumococcal serotypes
included in the available formulations ranged from
60-86% [37,39].
The pneumococcal serotypes targeted by PCV-7 and
PCV-13 comprise 47% (63% if 6A cross-protection is
assumed) and 76%, respectively, of the pneumococci
isolated from AOM samples in this study, and thus
14.1% (19.2% assuming 6A cross-protection) and 23.2%
of all AOM cases sampled in this study [21,25]. The
pneumococcal serotypes targeted by PHiD-CV also
Figure 3 Serotype distribution of S. pneumoniae (N = 30) positive isolates cultured from middle ear fluid samples. The pie chart shows
each serotypes of S. pneumoniae with their respective percentage of positive episodes.
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all AOM cases sampled; in addition, PHiD-CV also tar-
gets H. influenzae which represents an additional 27% of
all AOM cases sampled. It is important to note, how-
ever, that neither clinical efficacy nor effectiveness data
against AOM are available for either PHiD-CV or PCV-
13, and so the magnitude of the clinical impact of each
remains undetermined.
There were some limitations to the study. This study is
limited by a small sample size which affects the precision
of the estimates. In addition, the enrolled children were
recruited from private centers which might not be repre-
sentative of the entire Colombian population. However,
we note that both pathogen and serotype distribution are
similar to what has been seen in studies elsewhere.
Conclusions
In summary, H. influenzae (NTHi) and S. pneumoniae
were the most commonly isolated bacteria in the study in
all age groups. Vaccination could be an effective strategy
in Colombia for preventing AOM disease. Considering
the importance of H. influenzae as a causative agent of
AOM, a conjugate vaccine with efficacy against both H.
influenzae and S. pneumoniae could potentially prevent
most bacterial AOM among Colombian children.
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Figure 4 Antibacterial susceptibility of S. pneumoniae positive
samples to penicillin (ATP cohort). The susceptibility of each
S. pneumoniae serotype to penicillin for categories sensitive,
intermediate and resistant. *Minimum Inhibitory Concentration
Table 3 Antibacterial susceptibility of samples positive
for S. pneumoniae (ATP cohort)
Antibiotics Serotypes
6A n
(%)
14 n
(%)
19A n
(%)
19F n
(%)
Penicillin 3 (60) S
2 (40) I
3 (100)
I
1 (50) I
1 (50) R
8 (80) S
2 (20) I
Cefotaxime 2 (40) S 1 (33) S
2 (67) I
1 (50) R 7 (70) S
1 (10) I
Erythromycin 3 (60) S
2 (40) R
3 (100)
S
1 (50) S
1 (50) R
8 (80) S
2 (20) R
Chloramphenicol 5 (100)
S
3 (100)
S
2 (100) S 10 (100)
S
Tetracycline 5 (100)
S
2 (67) S
1 (33) I
1 (50) S,R 5 (50) S
5 (50) R
Levofloxacin 5 (100)
S
3 (100)
S
2 (100) S 10 (100)
S
Trimethoprim/
Sulfamethoxazole
4 (80) S
1 (20) R
3 (100)
R
1 (50) S,R 6 (60) S
3 (30) R
1 (10) I
Other 5 (100)
S
3 (100)
S
1 (100) S 9 (100) S
n = number of samples in a given category
(%) = n/Number of samples with results available * 100
S = sensitive; I = intermediate; R = resistant
NT = not tested
Note: None of the serotypes are tested for Amoxicillin/Clavulanate and
Cefuroxime; For serotype 6A, only 1 sample was sensitive for Azithromycin;
For serotypes 15A and 15B, only 1 sample was sensitive for each mentioned
antibiotic; Serotype 3 had 2 samples sensitive for each antibiotic and Not
Tested for Cefotaxime; Serotype 10A had 1 sample sensitive for all antibiotics;
Serotype 20 had 1 sample sensitive for all antibiotics, Not Tested for
Chloramphenicol and Missing for other; Serotype 16F and 23F had 1 sample
resistant to Tetracycline, 1 sample Not Tested for Cefotaxime, 1 missing for
Other and 1 sample sensitive for other antibiotics
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